GPD1

Across TCGA pan-cancer cohorts, GPD1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GPD1 data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher GPD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPD1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, UCEC, and BLCA are the cancer types where GPD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.224	0.692	<.001	43	view →
UCEC	DFS	Median	II,III,IV	1.000	0.440	.016	24	view →
BLCA	OS	Median	III,IV	0.132	0.684	<.001	18	view →
BRCA	OS	Median	II,III,IV	0.116	0.565	.004	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GPD1–STAD (OS)

Open the STAD breakdown →